Literature DB >> 17062698

The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

Marco Seandel, Jinru Shia, Irina Linkov, Robert G Maki, Cristina R Antonescu, Jakob Dupont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17062698     DOI： 10.1158/1078-0432.CCR-06-1292

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  10 in total

1.  Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.

Authors:  Peter B Makhov; Konstantin Golovine; Alexander Kutikov; Ervin Teper; Daniel J Canter; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

2.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

3.  Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Margaret A Schwarz; Roderich E Schwarz
Journal:  HPB (Oxford)       Date:  2011-06-07       Impact factor: 3.647

4.  Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

Authors:  Diego M Avella; Guangfu Li; Todd D Schell; Dai Liu; Samuel Shao-Min Zhang; Xi Lou; Arthur Berg; Eric T Kimchi; Hephzibah Rani S Tagaram; Qing Yang; Serene Shereef; Luis S Garcia; Mark Kester; Harriet C Isom; C Bart Rountree; Kevin F Staveley-O'Carroll
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

5.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

6.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.

Authors:  Hong Xin; Chunyan Zhang; Andreas Herrmann; Yan Du; Robert Figlin; Hua Yu
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

7.  Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Authors:  D Mahalingam; C M Espitia; E C Medina; J A Esquivel; K R Kelly; D Bearss; G Choy; P Taverna; J S Carew; F J Giles; S T Nawrocki
Journal:  Br J Cancer       Date:  2011-10-20       Impact factor: 7.640

8.  Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Winston Ruan; Margaret A Schwarz; Roderich E Schwarz
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

9.  Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.

Authors:  Zeshen Wu; Yulu Peng; Longbin Xiong; Jun Wang; Zhen Li; Kang Ning; Minhua Deng; Ning Wang; Wensu Wei; Zhiyong Li; Pei Dong; Chunping Yu; Fangjian Zhou; Zhiling Zhang
Journal:  Cancer Med       Date:  2022-04-10       Impact factor: 4.711

10.  The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.

Authors:  Neus Martínez-Bosch; Pedro Enrique Guerrero; Mireia Moreno; Anabel José; Mar Iglesias; Jessica Munné-Collado; Héctor Anta; Joan Gibert; Carlos Alberto Orozco; Judith Vinaixa; Cristina Fillat; Francesc Viñals; Pilar Navarro
Journal:  Oncotarget       Date:  2016-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.